We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Genentech, Tercica Prevail In Suit Against Insmed

Law360 (December 6, 2006, 12:00 AM EST) -- A California jury awarded $7.5 million plus royalties to biotechnology company Genentech Inc. and its licensee, Tercica Inc, after a “clean sweep” verdict that found a rival start-up infringed its patents for a drug used to treat hormone-deficiency in children, lawyers said Thursday.

After an 11-day trial and seven days of deliberations, the jury ordered defendant Insmed Inc. to pay the Silicon Valley partners 15% royalties on up to $100 million in sales of its Iplex drug for short stature, plus 20% royalties for sales beyond...
To view the full article, register now.